R&D strength

Based on our mature R & D platform for innovative drugs and high-barrier complex formulations, we have made a rich pipeline layout around disease areas with significant clinical needs such as (i) assisted reproduction, (ii) digestive tract, (iii) respiratory system, (iv) mental and neurological, and (v) tumors. As of June 30, 2022, we have established 249 pipeline projects, of which 26 have entered the clinical stage.

As of 2023, we have 8 pipeline products for sustained-release microspheres, including (i) Aripiprazole microspheres for first-line antipsychotic drug injection, which are currently being applied for production. Currently, there are no competitive sustained-release microsphere products in China; and (ii) our products and (ii) Tripralin acetate microspheres for injection, which have been approved for prostate cancer indications and have completed Phase III clinical trials for endometriosis and applied for production.

Inhalation preparation product pipeline: We have a comprehensive layout of inhalation preparation products with extremely low penetration rates that are highly dependent on imports. Currently, our inhalation preparation pipeline has 10 varieties of products on the market, and more than 20 varieties in the respiratory field are under research, successfully covering all categories of inhalation therapy drugs for asthma and chronic obstructive pulmonary disease. These include (i) tobramycin inhalation solution, which has become the first inhalation antibiotic approved for marketing in China; (ii) salmeterolitecasone inhalation powder is one of the most difficult drugs to imitate, and has obtained a drug registration certificate; and (iii) the marketing application for innovative anti-influenza drug TG-1000 capsules has been accepted. 

Digestive PPI drug pipeline: We are further developing new dosage forms and indications for the eprazole series of products.

Biopharmaceutical product pipeline: As of 2023, our drug pipeline has a total of 6 types, including (i) injectable recombinant human chorionic gonadotropin α, which became the first generic drug approved for marketing in China; (ii) tocilizumab injection has been approved for marketing; (iii) recombinant anti-human IL-17A/F humanized monoclonal antibody injection is undergoing Phase III clinical trials; (iv) COVID-19 vaccine Likang V-01, which uses interferon natural adjuvant and has enhanced protection against the Omicron variant. In September 2022, it was included in the emergency use of sequential booster immunization and became the second approved recombinant vaccine in China; (v) Recombinant human follicle-stimulating hormone injection is undergoing Phase III clinical trials.